RecruitingNCT03817502
Cariprazine study in adolescents with schizophrenia
About this title
Read the official source — NCT03817502Researchers are comparing Cariprazine and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Medication studyAges 13–17Multiple countries
Understand this study
What is this study about?
Researchers are comparing Cariprazine and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Who could participate?
Listed age limits: 13 years to 17 years.
- Listed locations
- Culver City and 56 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 6, 2019
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 330
- Sponsor
- Gedeon Richter Plc.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Colombia, ...
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT03817502
- Official title
Show the full official title
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Culver City, United States · Atlanta, United States · Bloomfield Hills, United States
45 more locations
- Flowood, United States
- Buffalo, United States
- New York, United States
- Cincinnati, United States
- The Woodlands, United States
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Pereira, Colombia
- Culiacán, Mexico
- Durango, Mexico
- Guadalajara, Mexico
- Guanajuato City, Mexico
- Mérida, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Iași, Romania
- Timișoara, Romania
- Arkhangelsk, Russia
- Kazan', Russia
- Krasnodar, Russia
- Lipetsk, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Roshchino, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Smolensk, Russia
- Stavropol, Russia
- Tomsk, Russia
- Tonnel'nyy, Russia
- Yaroslavl Region, Russia
- Belgrade, Serbia
- Novi Sad, Serbia
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Vinnytsia, Ukraine
- Russia
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Cariprazine and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Who is behind this study?
The study sponsor is Gedeon Richter Plc.
Does this study involve medication?
Yes. The study involves medication, including Cariprazine and Placebo.
Who can participate?
Listed age limits: 13 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....